Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC.ITEK · Entity 5627 | Director | June 20, 2017 | June 21, 2017 |
| TherapeuticsMD, Inc.TXMD · Entity 7541 | Director | August 10, 2021 | August 13, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ROCKET PHARMACEUTICALS, INC.
Report date June 20, 2017 · Filed June 21, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2027-06-19 | Direct | 45,000 |
Reported balance
After 2017-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-06-20 · Grant · Acquired 45,000 · Balance 45,000 F1: This stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan. The option shall vest in equal quarterly installments at the end of each quarter following June 20, 2017, subject to continued service through such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option award was issued pursuant to Inotek Pharmaceuticals Corporation's 2014 Stock Option and Incentive Plan. The option shall vest in equal quarterly installments at the end of each quarter following June 20, 2017, subject to continued service through such dates.
TherapeuticsMD, Inc.
Report date August 10, 2021 · Filed August 13, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 106,864 |
Reported balance
After 2021-08-10 transaction · row 1
1 source rowRow 1 · 2021-08-10 · Exercise / conversion · Acquired 96,864 · Balance 106,864 F1: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-08-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-08-10 · Exercise / conversion · Disposed 96,864 · Balance 0 F1: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. F2: Each RSU represented a contingent right to receive one share of issuer common stock upon settlement. F3: The RSUs vested on June 18, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021.
F2: Each RSU represented a contingent right to receive one share of issuer common stock upon settlement.
F3: The RSUs vested on June 18, 2021.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Catalent, Inc.
Report date December 18, 2024 · Filed December 18, 2024
Section 16 reporting ended · disclosed 2024-12-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-12-18 transaction · row 1
1 source rowRow 1 · 2024-12-18 · Disposition to issuer · Disposed 32,734 · Balance 0 F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F2: Includes restricted stock units ("RSUs"). F3: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the "Merger Consideration"). F4: At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger").
F2: Includes restricted stock units ("RSUs").
F3: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the "Merger Consideration").
F4: At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms.
Esperion Therapeutics, Inc.
Report date July 13, 2026 · Filed July 13, 2026
Section 16 reporting ended · disclosed 2026-07-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 1
1 source rowRow 1 · 2026-07-13 · Disposition to issuer · Disposed 177,523 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F2: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F3: Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.37 · Expires 2033-06-15 | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-13 · Disposition to issuer · Disposed 21,000 · Balance 0 F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2034-05-23 | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-13 · Disposition to issuer · Disposed 32,500 · Balance 0 F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.87 · Expires 2035-05-29 | Direct | 0 |
Reported balance
After 2026-07-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-13 · Disposition to issuer · Disposed 44,000 · Balance 0 F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.
F2: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled.
F3: Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions.
F4: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR.
Keenova Therapeutics plc
Report date June 16, 2022 · Filed June 21, 2022
Section 16 reporting ended · disclosed 2022-06-21. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 13, 2026 Filed Jul 13, 2026 20:05 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Disposition to issuerStock Option (right to buy) · Derivative | 44,000 | Not disclosed Strike: $0.87 | Not disclosed |
DisclosureSEC source: 0001628280-26-048012 · wk-form4_1783973150.xml · derivative · entry 4 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,000 shares Expires 2035-05-29 F4 · derivative.exercise_price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1 · kind: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F4 · price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F4 · derivative.exercise_date: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. Read SEC document |
| July 13, 2026 Filed Jul 13, 2026 20:05 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Disposition to issuerStock Option (right to buy) · Derivative | 32,500 | Not disclosed Strike: $2.25 | Not disclosed |
DisclosureSEC source: 0001628280-26-048012 · wk-form4_1783973150.xml · derivative · entry 3 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,500 shares Expires 2034-05-23 F4 · derivative.exercise_price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1 · kind: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F4 · price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F4 · derivative.exercise_date: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. Read SEC document |
| July 13, 2026 Filed Jul 13, 2026 20:05 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Disposition to issuerStock Option (right to buy) · Derivative | 21,000 | Not disclosed Strike: $1.37 | Not disclosed |
DisclosureSEC source: 0001628280-26-048012 · wk-form4_1783973150.xml · derivative · entry 2 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,000 shares Expires 2033-06-15 F4 · derivative.exercise_price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F1 · kind: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F4 · price: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. F4 · derivative.exercise_date: At the Effective Time, each stock option having a per share exercise price that was less than the per share cash consideration (each, an "in-the-money option") was canceled and converted into the right to receive, for each share of Common Stock issuable upon the exercise of such in-the-money option immediately prior to the Effective Time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the excess of the per share cash consideration over the per share exercise price of such in-the-money option plus (b) one CVR. Read SEC document |
| July 13, 2026 Filed Jul 13, 2026 20:05 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | Disposition to issuerCommon Stock | 177,523 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-048012 · wk-form4_1783973150.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 1, 2026, by and among the Issuer, Essence Parent Inc., a Delaware corporation ("Parent") and Essence MergerCo Inc., a Delaware corporation and wholly owned subsidiary of Parent ("MergerCo"), pursuant to which, on July 13, 2026 (the "Effective Time"), MergerCo merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent. F2 · shares: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F3 · shares: Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions. F2 · price: At the Effective Time, each share of the Issuer's common stock, par value $0.001 per share ("Common Stock") was converted into the right to receive (a) an amount in cash equal to $3.16 per share, without interest (the "per share cash consideration"), and (b) one contractual contingent value right per share (each, a "CVR" and, together with the per share cash consideration, the "merger consideration"), representing the right to participate in contingent payments in cash, without interest, upon the achievement of certain milestones, subject to any applicable withholding taxes. From and after the Effective Time, all such shares of Common Stock were no longer outstanding and were automatically canceled. F3 · price: Includes 79,873 restricted stock units (each, a "RSU"). At the Effective Time, each RSU with respect to Common Stock outstanding immediately prior to the Effective Time vested in full (to the extent then-unvested), and was canceled and converted into the right to receive, with respect to each share of Common Stock subject to such RSU immediately prior to the effective time, (a) a cash payment (rounded down to the nearest cent), without interest and subject to applicable tax withholding and deductions, equal to the per share cash consideration, plus (b) one CVR, subject to certain exceptions. Read SEC document |
| May 28, 2026 Filed Jun 1, 2026 20:22 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 79,873 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-039520 · wk-form4_1780345352.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,523 F1 · shares: The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:10 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 44,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001628280-25-028830 · wk-form4_1748895041.xml · derivative · entry 2 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2035-05-29 F1 · derivative.exercise_date: The awards vest in full on the earlier of (i) May 29, 2026 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2025. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 20:10 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 33,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-028830 · wk-form4_1748895041.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,650 F1 · shares: The awards vest in full on the earlier of (i) May 29, 2026 and (ii) the Issuer's next annual meeting of stockholders following May 29, 2025. Read SEC document |
| December 18, 2024 Filed Dec 18, 2024 17:57 UTC | Catalent, Inc. CTLT · Entity 16279 | Disposition to issuerCommon Stock | 32,734 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-137708 · ownership.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 18, 2024, Creek Parent, Inc., a Delaware corporation ("Parent"), acquired the Issuer pursuant to that certain Agreement and Plan of Merger entered into by and among the Issuer, Parent and Creek Merger Sub, Inc., a Delaware corporation and a wholly owned Subsidiary of Parent ("Merger Sub"), dated as of February 5, 2024 (the "Merger Agreement"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving such merger as a wholly-owned subsidiary of Parent (the "Merger"). F2 · shares: Includes restricted stock units ("RSUs"). F3 · price: At the effective time of the Merger (the "Effective Time"), each outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $63.50 in cash, without interest (the "Merger Consideration"). F4 · price: At the Effective Time, each RSU, whether or not vested, outstanding immediately prior to the Effective Time vested (if unvested) and was cancelled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the total number of shares of Issuer common stock subject to the RSU multiplied by (ii) the Merger Consideration, except for certain RSUs granted following the date of the Merger Agreement which were converted at the Effective Time into restricted cash awards equal to the product of (a) the Merger Consideration multiplied by (b) the number of shares of Issuer common stock subject to such award and otherwise remain subject to their terms, including vesting and acceleration terms. Read SEC document |
| October 30, 2024 Filed Nov 1, 2024 21:04 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 4,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-24-000101 · wk-form4_1730495055.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,734 F1 · shares: The equity acquired by the reporting person is the annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-employee director compensation program. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur on the earlier of (i) a "change in control" (as defined in the Catalent, Inc. 2018 Omnibus Incentive Plan) and (ii) one year from the date of award, subject to continued service. F2 · balance_after: Includes restricted stock units. Read SEC document |
| May 23, 2024 Filed May 24, 2024 20:18 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 32,500 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001628280-24-025223 · wk-form4_1716581904.xml · derivative · entry 2 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 32,500 shares Expires 2034-05-23 F1 · derivative.exercise_date: The awards vest in full on the earlier of (i) May 23, 2025 and (ii) the Issuer's next annual meeting of stockholders following May 23, 2024. Read SEC document |
| May 23, 2024 Filed May 24, 2024 20:18 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-025223 · wk-form4_1716581904.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,650 F1 · shares: The awards vest in full on the earlier of (i) May 23, 2025 and (ii) the Issuer's next annual meeting of stockholders following May 23, 2024. Read SEC document |
| October 27, 2023 Filed Oct 31, 2023 21:04 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 6,993 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-23-000159 · wk-form4_1698786289.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,071 F1 · shares: The equity acquired by the reporting person is the annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-employee director compensation program. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award, subject to continued service. F2 · balance_after: Includes restricted stock units. Read SEC document |
| July 01, 2023 Filed Jul 7, 2023 20:41 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 555 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-23-000044 · wf-form4_168876245096139.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,078 F1 · shares: The equity acquired by the reporting person is the regular, annual grant of restricted stock units (pro-rated to reflect a partial year of service in a new role) provided by the Issuer to the reporting person pursuant to the Issuer's non-management director compensation package. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award. F2 · balance_after: Includes restricted stock units. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:08 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 21,000 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001628280-23-022457 · wf-form4_168694606782252.xml · derivative · entry 2 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2033-06-15 F1 · derivative.exercise_date: The awards vest in full on the earlier of (i) June 15, 2024 and (ii) the Issuer's next annual meeting of stockholders following June 15, 2023. Read SEC document |
| June 15, 2023 Filed Jun 16, 2023 20:08 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantCommon Stock | 5,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-022457 · wf-form4_168694606782252.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,650 F1 · shares: The awards vest in full on the earlier of (i) June 15, 2024 and (ii) the Issuer's next annual meeting of stockholders following June 15, 2023. Read SEC document |
| May 11, 2023 Filed May 11, 2023 20:11 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 23,091 | $1.57 | $36,285.20 |
DisclosureSEC source: 0001628280-23-017563 · wf-form4_168383586976164.xml · nonDerivative · entry 2 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,500 Read SEC document |
| May 10, 2023 Filed May 11, 2023 20:11 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 8,409 | $1.49 | $12,545.39 |
DisclosureSEC source: 0001628280-23-017563 · wf-form4_168383586976164.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,409 Read SEC document |
| October 27, 2022 Filed Oct 31, 2022 20:40 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 4,149 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-22-000163 · wf-form4_166724880116085.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,523 F1 · kind: The equity acquired by the reporting person is the regular, annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-employee director compensation package. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur on the earlier of one year from the date of award and the date of the Issuer's fiscal 2023 annual meeting of shareholders. F2 · balance_after: Includes restricted stock units. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:11 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | PurchaseCommon Stock | 5,000 | $5.64 | $28,179.50 |
DisclosureSEC source: 0001628280-22-016165 · wf-form4_165428708283768.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Read SEC document |
| June 01, 2022 Filed Jun 1, 2022 20:24 UTC | Esperion Therapeutics, Inc. ESPR · Entity 30796 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.42 | $0.00 |
DisclosureSEC source: 0001628280-22-015913 · wf-form4_165411505026295.xml · derivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: The awards vest over a three (3) year period in equal annual installments, the first of which will be June 1, 2023. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 18:41 UTC | Catalent, Inc. CTLT · Entity 16279 | OtherCommon Stock | 3,136 | $134.12 | $420,600.32 |
DisclosureSEC source: 0001596783-21-000194 · wf-form4_163838409585752.xml · nonDerivative · entry 4 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 11,663 F2 · kind: The transaction involves the transfer of shares of the Issuer's common stock to a trust in exchange for assets of equal value. F3 · price: The average of the low and high price for the Issuer's common stock on the date of transfer. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 18:41 UTC | Catalent, Inc. CTLT · Entity 16279 | OtherCommon Stock | 3,136 | $134.12 | $420,600.32 |
DisclosureSEC source: 0001596783-21-000194 · wf-form4_163838409585752.xml · nonDerivative · entry 3 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 F2 · kind: The transaction involves the transfer of shares of the Issuer's common stock to a trust in exchange for assets of equal value. F3 · price: The average of the low and high price for the Issuer's common stock on the date of transfer. Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 18:41 UTC | Catalent, Inc. CTLT · Entity 16279 | GiftCommon Stock | 3,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-21-000194 · wf-form4_163838409585752.xml · nonDerivative · entry 2 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 3,136 Read SEC document |
| November 29, 2021 Filed Dec 1, 2021 18:41 UTC | Catalent, Inc. CTLT · Entity 16279 | GiftCommon Stock | 3,136 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-21-000194 · wf-form4_163838409585752.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,374 F1 · balance_after: Includes restricted stock units. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 11:59 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 1,402 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-21-000169 · wf-form4_163576796826101.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,510 F1 · kind: The equity acquired by the reporting person is the regular, annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-management director compensation package. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur on the earlier of one year from the date of award and the date of the Issuer's fiscal 2022 annual meeting of shareholders. F2 · balance_after: Includes restricted stock units. Read SEC document |
| August 10, 2021 Filed Aug 13, 2021 01:27 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionRestricted Stock Units · Derivative | 96,864 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-21-008434 · ownership.xml · derivative · entry 2 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,864 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. F2 · shares: Each RSU represented a contingent right to receive one share of issuer common stock upon settlement. F3 · derivative.exercise_date: The RSUs vested on June 18, 2021. F3 · derivative.expiration_date: The RSUs vested on June 18, 2021. F1 · derivative.underlying_shares: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. F2 · derivative.underlying_shares: Each RSU represented a contingent right to receive one share of issuer common stock upon settlement. Read SEC document |
| August 10, 2021 Filed Aug 13, 2021 01:27 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | Exercise / conversionCommon Stock | 96,864 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001387131-21-008434 · ownership.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,864 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On August 10, 2021, the reporting person received 96,864 shares of common stock of the issuer in settlement of restricted stock units (RSUs), which vested on June 18, 2021. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 22:11 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 99,174 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-21-007137 · ownership.xml · derivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,174 Underlying: Common Stock · 99,174 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on July 1, 2022. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on July 1, 2022. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:17 UTC | Keenova Therapeutics plc MNKKQ · Entity 28960 | SaleOrdinary Shares | 31,398 | $0.40 | $12,581.18 |
DisclosureSEC source: 0000950138-21-000222 · edgar.xml · nonDerivative · entry 2 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 F1 · price: The price represents a weighted average. The shares were sold in multiple transactions at prices ranging from $0.40 to $0.41, inclusive. Mr. Carroll will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:17 UTC | Keenova Therapeutics plc MNKKQ · Entity 28960 | SaleOrdinary Shares | 10,667 | $0.40 | $4,274.27 |
DisclosureSEC source: 0000950138-21-000222 · edgar.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price represents a weighted average. The shares were sold in multiple transactions at prices ranging from $0.40 to $0.41, inclusive. Mr. Carroll will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range. Read SEC document |
| October 29, 2020 Filed Nov 2, 2020 12:20 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 2,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-20-000210 · wf-form4_160431959725529.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,108 F1 · kind: The equity acquired by the reporting person is the regular, annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-management director compensation package. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur on the earlier of one year from the date of award and the date of the Issuer's fiscal 2021 annual meeting of shareholders. F2 · balance_after: Includes restricted stock units. Read SEC document |
| August 27, 2020 Filed Aug 28, 2020 22:45 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 661 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-20-000140 · wf-form4_159865474314284.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,983 F1 · kind: The equity acquired by the reporting person is part of the regular, annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-management director compensation package. The grant is in respect of the period between July 1, 2020 and the date of the reporting person's annual meeting of shareholders in respect of fiscal 2020. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award. F2 · balance_after: Includes restricted stock units. Read SEC document |
| June 18, 2020 Filed Jun 19, 2020 21:07 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantRestricted Stock Units · Derivative | 96,864 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001387131-20-005815 · ownership.xml · derivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,864 Underlying: Common Stock · 96,864 shares Expires not disclosed F1 · derivative.exercise_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on June 18, 2021. F1 · derivative.expiration_date: Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs will vest on June 18, 2021. Read SEC document |
| May 13, 2020 Filed May 15, 2020 20:13 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 8,729 | $2.96 | $25,837.84 |
DisclosureSEC source: 0000950138-20-000255 · edgar.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,667 Read SEC document |
| May 12, 2020 Filed May 13, 2020 21:08 UTC | Catalent, Inc. CTLT · Entity 16279 | OtherCommon Stock | 3,600 | $72.29 | $260,244.00 |
DisclosureSEC source: 0001596783-20-000058 · wf-form4_158940406188101.xml · nonDerivative · entry 4 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 8,527 F2 · kind: The transaction involves the transfer of shares of the Issuer's common stock to a trust in exchange for assets of equal value. F3 · price: The average of the low and high price for the Issuer's common stock on the date of transfer. Read SEC document |
| May 12, 2020 Filed May 13, 2020 21:08 UTC | Catalent, Inc. CTLT · Entity 16279 | OtherCommon Stock | 3,600 | $72.29 | $260,244.00 |
DisclosureSEC source: 0001596783-20-000058 · wf-form4_158940406188101.xml · nonDerivative · entry 3 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 F2 · kind: The transaction involves the transfer of shares of the Issuer's common stock to a trust in exchange for assets of equal value. F3 · price: The average of the low and high price for the Issuer's common stock on the date of transfer. Read SEC document |
| May 12, 2020 Filed May 13, 2020 21:08 UTC | Catalent, Inc. CTLT · Entity 16279 | GiftCommon Stock | 3,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-20-000058 · wf-form4_158940406188101.xml · nonDerivative · entry 2 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 3,600 Read SEC document |
| May 12, 2020 Filed May 13, 2020 21:08 UTC | Catalent, Inc. CTLT · Entity 16279 | GiftCommon Stock | 3,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-20-000058 · wf-form4_158940406188101.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,322 F1 · balance_after: Includes restricted stock units. Read SEC document |
| August 22, 2019 Filed Aug 26, 2019 19:45 UTC | Catalent, Inc. CTLT · Entity 16279 | GrantCommon Stock | 3,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-19-000151 · wf-form4_156684871922500.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,922 F1 · kind: The equity acquired by the reporting person is the regular, annual grant of restricted stock units provided by the Issuer to the reporting person pursuant to the Issuer's non-management director compensation package. Each restricted stock unit represents the right to receive one share of the Issuer's common stock as of the date of vesting, which will occur one year from the date of award. F2 · balance_after: Includes restricted stock units. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 22:53 UTC | Catalent, Inc. CTLT · Entity 16279 | OtherCommon Stock | 4,927 | $53.24 | $262,313.48 |
DisclosureSEC source: 0001596783-19-000061 · wf-form4_156340399171917.xml · nonDerivative · entry 4 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By trust Disclosed balance after: 4,927 F2 · kind: The transaction involves the transfer of shares of the Issuer's common stock to a trust in exchange for assets of equal value. F3 · price: The average of the low and high price for the Issuer's common stock on the date of transfer. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 22:53 UTC | Catalent, Inc. CTLT · Entity 16279 | OtherCommon Stock | 4,927 | $53.24 | $262,313.48 |
DisclosureSEC source: 0001596783-19-000061 · wf-form4_156340399171917.xml · nonDerivative · entry 3 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 F2 · kind: The transaction involves the transfer of shares of the Issuer's common stock to a trust in exchange for assets of equal value. F3 · price: The average of the low and high price for the Issuer's common stock on the date of transfer. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 22:53 UTC | Catalent, Inc. CTLT · Entity 16279 | GiftCommon Stock | 4,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-19-000061 · wf-form4_156340399171917.xml · nonDerivative · entry 2 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 4,927 Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 22:53 UTC | Catalent, Inc. CTLT · Entity 16279 | GiftCommon Stock | 4,927 | $0.00 | $0.00 |
DisclosureSEC source: 0001596783-19-000061 · wf-form4_156340399171917.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,755 F1 · balance_after: Includes restricted stock units. Read SEC document |
| June 20, 2019 Filed Jun 24, 2019 23:01 UTC | TherapeuticsMD, Inc. TXMD · Entity 7541 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $2.64 | $0.00 |
DisclosureSEC source: 0001387131-19-004584 · carroll-form4_062019.xml · derivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-06-20 Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 20:14 UTC | Keenova Therapeutics plc MNK · Entity 28960 | OtherOrdinary Shares | 10,551 | $9.19 | $96,963.69 |
DisclosureSEC source: 0000950138-19-000331 · edgar.xml · nonDerivative · entry 4 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 31,398 F1 · kind: The transaction involves the transfer of ordinary shares to trust in exchange for assets of equal value. F2 · balance_after: Updated to reflect an additional 360 ordinary shares held by trust that were inadvertently omitted from previous filing due to a typographical error. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 20:14 UTC | Keenova Therapeutics plc MNK · Entity 28960 | OtherOrdinary Shares | 10,551 | $9.19 | $96,963.69 |
DisclosureSEC source: 0000950138-19-000331 · edgar.xml · nonDerivative · entry 3 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 F1 · kind: The transaction involves the transfer of ordinary shares to trust in exchange for assets of equal value. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 20:14 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GiftOrdinary Shares | 10,551 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000331 · edgar.xml · nonDerivative · entry 2 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 10,551 Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 20:14 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GiftOrdinary Shares | 10,551 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000331 · edgar.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,396 F2 · balance_after: Updated to reflect an additional 360 ordinary shares held by trust that were inadvertently omitted from previous filing due to a typographical error. Read SEC document |
| May 15, 2019 Filed May 17, 2019 10:49 UTC | Keenova Therapeutics plc MNK · Entity 28960 | GrantOrdinary Shares | 19,396 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000306 · edgar.xml · nonDerivative · entry 2 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,307 F1 · shares: Consists of restricted stock units that vest in their entirety as of the date of the Company's 2020 Annual General Meeting. The restricted stock units settle in ordinary shares upon vesting. Read SEC document |
| May 15, 2019 Filed May 17, 2019 10:49 UTC | Keenova Therapeutics plc MNK · Entity 28960 | Tax withholdingOrdinary Shares | 8,527 | $15.21 | $129,695.67 |
DisclosureSEC source: 0000950138-19-000306 · edgar.xml · nonDerivative · entry 1 CARROLL J MARTIN · CIK 0001279901 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,911 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.